Sensei Biotherapeutics (NASDAQ:FTH) Price Target Raised to $60.00

Sensei Biotherapeutics (NASDAQ:FTH) had its price objective boosted by Citigroup from $55.00 to $60.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Other analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. Needham & Company LLC began coverage on Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 price target on the stock. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target for the company. Oppenheimer began coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price target for the company. Finally, Lifesci Capital upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $56.58.

Sensei Biotherapeutics Stock Performance

FTH opened at $10.65 on Tuesday. The company’s fifty day moving average price is $25.65. The firm has a market cap of $275.20 million, a price-to-earnings ratio of -0.08 and a beta of -0.15. Sensei Biotherapeutics has a twelve month low of $7.45 and a twelve month high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). Analysts forecast that Sensei Biotherapeutics will post -13.35 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp acquired a new stake in shares of Sensei Biotherapeutics in the third quarter valued at approximately $9,262,000. Candriam S.C.A. acquired a new position in shares of Sensei Biotherapeutics during the third quarter worth approximately $9,542,000. State of Wyoming bought a new position in Sensei Biotherapeutics in the 3rd quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. grew its holdings in Sensei Biotherapeutics by 48.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company’s stock worth $150,000 after buying an additional 1,760 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in Sensei Biotherapeutics in the 2nd quarter worth approximately $307,000. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.